Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634452 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma
A Phase 1 study of Hodgkin's Lymphomas, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 6
- Study locations
NCT00634452 is a Phase 1 study of Hodgkin's Lymphomas that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 22 participants. The trial reports 6 study locations across 6 states.
The verdict
NCT00634452, a Phase 1 study of Hodgkin's Lymphomas, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 6
- Study locations
Study Summary
To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).
Conditions Studied
Interventions
- BIOLOGICAL MDX-1401
Study Locations (6)
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- ClinWorks Cancer Research Center - Charlotte
Texas
- Scott and White Memorial Hospital and Clinic - Temple
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634452
The ClinicalTrials.gov registry entry for NCT00634452 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hodgkin's Lymphomas appearing as the primary indexed condition, and to 1 intervention - of which MDX-1401 is the first listed.
NCT00634452 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00634452 about?
NCT00634452 is a clinical study titled "Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma". To establish the safety and tolerability profile of MDX-1401 in patients with relapsed or refractory Hodgkin's Lymphoma (HL).
What is the current status of trial NCT00634452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-02. Estimated completion is 2010-01.
What conditions does trial NCT00634452 study?
This clinical trial studies the following conditions: Hodgkin's Lymphomas.
What interventions are being tested in trial NCT00634452?
The interventions under investigation include: MDX-1401 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00634452?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00634452 being conducted?
This trial has 6 study locations across Georgia, Illinois, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.